Charles River Laboratories International, Inc.
NYSE:CRLMedical - Diagnostics & Research
-$2.45 today
- Market cap
- $15.97B
- Beta
- 1.45
- P/E (TTM)
- -48.3
- EPS (TTM)
- -$3.77
Volume 0.52M
Average 0.86M
CRL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Charles River Laboratories International, Inc.NYSE: CRL
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA declines year over year
Q2 FY2026 EBITDA of $150.8M fell 31.7% year over year, ahead of the -58.3% change in trailing-twelve-month EBITDA. Sequentially, it rose 135.8% from the prior quarter. Over 3 fiscal years it compounded at -25.3% a year.
Context
- EBITDA amounted to 10.2% of revenue in FY2025, down 4.1 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 10 analysts of $1.3B (+216.9%) for the fiscal year ending Dec 2026, a step up from the -29.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $150.8M+135.8% QoQ
- Last fiscal yearDec 2025
- $410.84M-29.3% YoY
- LTMJun 2026
- $220.47M-58.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -31.7% | +54.7% | +86.4 pp |
| 1 year | -29.3% | +216.9% | +246.2 pp |
| 3-year CAGR | -25.3% | +53.1% | +78.4 pp |
| 5-year CAGR | +33.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 410.84M USD
- Year-over-year change
- -29.3%
- 4-year CAGR
- -15.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-27 | 410.84M | -29.3% |
| FY2024 | 2024-12-28 | 581.14M | -43.7% |
| FY2023 | 2023-12-31 | 1.03B | +4.7% |
| FY2022 | 2022-12-31 | 986.15M | +20.2% |
| FY2021 | 2021-12-31 | 820.16M | — |
EBITDA vs competitors
How CRL compares with its peers on the latest reported figures
- CRL's LTM Jun 2026 EBITDA of $220.47M is the 3rd highest of the 4 companies compared; the peer median is $643.55M.
- Its year-over-year change of -58.3% is the lowest of 4, against a peer median of +17.5%.
- EBITDA amounts to 5.5% of revenue for CRL, versus a peer median of 22.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.25B | -9.3% | -15.5% | 15.1% | |
| LTM Sep 2026 | $643.55M | +17.5% | +22.8% | 22.7% | |
| LTM Jun 2026 | $220.47M | -58.3% | -25.3% | 5.5% | |
| LTM Mar 2026 | $101.27M | +78.1% | -1.9% | 24.1% | |
| Peer median (excluding CRL) | $643.55M | +17.5% | -1.9% | 22.7% | |
Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.54B | 3.98B | 4.13B | 4.05B | 4.02B |
| Cost of Revenue | 2.21B | 2.51B | 2.63B | 2.72B | 2.79B |
| Gross Profit | 1.33B | 1.46B | 1.5B | 1.33B | 1.23B |
| Gross Margin | 37.7% | 36.8% | 36.4% | 32.9% | 30.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 619.92M | 665.1M | 747.86M | 751M | 743.07M |
| Operating Expenses | 744.78M | 811.68M | 885.3M | 1.1B | 717.73M |
| Depreciation & Amortization | 265.54M | 303.87M | 314.12M | 361.74M | 403.31M |
| EBITDA | 820.16M | 986.15M | 1.03B | 581.14M | 410.84M |
| EBITDA Margin | 23.2% | 24.8% | 25.0% | 14.3% | 10.2% |
| Operating Income | 589.86M | 650.98M | 617.26M | 227.35M | 507.84M |
| Operating Margin | 16.7% | 16.4% | 14.9% | 5.6% | 12.6% |
| Interest Income | 652K | 780K | 5.2M | 8.58M | 4.94M |
| Interest Expense | 73.91M | 59.29M | 136.71M | 126.29M | 107.03M |
| Other Income / Expenses | (109.15M) | (27.99M) | (35.98M) | (134.23M) | (607.34M) |
| Income Before Tax | 480.71M | 622.99M | 581.28M | 93.11M | (99.5M) |
| Pre-Tax Margin | 13.6% | 15.7% | 14.1% | 2.3% | -2.5% |
| Income Tax Expense | 81.87M | 130.38M | 100.91M | 67.82M | 42.66M |
| Net Income | 390.98M | 486.23M | 474.62M | 10.3M | (144.34M) |
| Net Margin | 11.0% | 12.2% | 11.5% | 0.3% | -3.6% |
| EPS (Basic) | 7.77 | 9.57 | 9.27 | 0.20 | (2.91) |
| EPS (Diluted) | 7.60 | 9.48 | 9.22 | 0.20 | (2.91) |
| Weighted Avg Shares | 50.29M | 50.81M | 51.23M | 51.38M | 49.56M |
| Weighted Avg Shares (Diluted) | 51.43M | 51.3M | 51.45M | 51.63M | 49.56M |
Charles River Laboratories International, Inc.
NYSE:CRL
Intrinsic Alpha fair value
Locked
Current Price
$333.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.